![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pfizer Nabs Extended Indication for Prevnar 13
Pfizer Nabs Extended Indication for Prevnar 13
![pfizerlogo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/pfizerlogo.gif?t=1576044507&width=430)
July 20, 2016
Pfizer has received the greenlight from the FDA to stretch the age indication for its pneumococcal 13-valent conjugate vaccine Prevnar 13, to include adults between the ages of 18 and 49.
The vaccine — which is designed to prevent pneumonia and invasive diseases caused by streptococcus pneumoniae — is now the only pneumococcal vaccine approved for patients aged 6 weeks and over, according to the company.
Upcoming Events
-
21Oct